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WILLINGNESS TO PARTICIPATE IN
SOUTH AFRICAN HIV VACCINE
TRIALS - CONCERNS OF MEDICAL
PROFESSIONALS IN THE WESTERN
CAPE
Keymanthri Moodley, Jo Bames, Estrelita Janse van
Rensburg, Landon Myer
Objectives. To evaluate the willingness of medical doctors
working at a tertiary hospital to participate in HlV vaccine
trials, their perceptions of patients' willingness to
participate, and the major reasons underlying these views.
Design. A self-administered, anonymous postal survey
conducted in two rounds between May and July 2001.
Setting. A tertiary care hospital in the Western Cape.
Subjects. All medical doctors listed on the hospital's staff
directory.
Outcome measures. Willingness to participate in, and to
recruit patients into, HlV vaccine trials, and the reasons for
this.
Results and conclusions. Of the 289 individuals surveyed,
80% stated either that they would not be willing to
participate in HlV vaccine trials or that they were unsure
about their participation. Meanwhile, 37% stated that they
would be willing to recruit patients into vaccine trials. The
most common concerns with trial participation were the
possibility of vaccine-induced infection and the possibility
of testing positive for antibodies to HlV The surprisingly
low level of willingness to participate in trials in this
sample of medical professionals highlights the importance
of preparatory work to overcome substantial barriers to
HlV vaccine trial participation.
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HlV vaccine trials are being planned in South Africa, and large-
scale phase III trials are likely to begin in the next few years.
While South Africa is considered an 'ideal' venue for EN
vaccine trials because of its relatively high HlV seroincidence,
it is likely that local vaccine trials will be fraught with
misperceptions and numerous barriers to trial participation,'
with individuals' willingness to participate in trials influenced
by the provision of accurate and appropriate information
addressing their fears and concerns.' Despite the growing body
of evidence demonstrating the importance of perceptioI}-s of
HlV vaccines in shaping the decision to participate in trials,'·-
there have been no published data from South Africa on
(mis-)perceptions of HlV vaccines, or on the willingness of
different South African populations to participate in vaccine
trials.
The willingness of medical doctors to participate in vaccine
trials is particularly important, both because doctors represent
a high-risk potential study population (given their
occupational exposure to HlV), and because doctors and other
health care workers are likely to be important 'gatekeepers'
involved in shaping community norms as well as recruiting
patients into HlV vaccine trials. lf medical doctors are
unwilling to be involved in HlV vaccine studies, this may
present a significant barrier to trial recruitment. We undertook
a survey to document the willingness of medical doctors
working in a tertiary hospital to participate in HlV vaccine
. trials, their willingness to recruit patients as trial participants,
and the reasons underlying these decisions.
METHODS
A self-administered postal survey was conducted at a tertiary
care hospital in the Western Cape between May and July 2001.
A list of all medical doctors working at the hospital (N = 488)
was obtained from the provincial and hospital administration.
The survey comprised two rounds - a first mailing, and then a
second mailing sent to those who did not respond to the first
mailing.
The documents sent out to each participant in the first
mailing contained a covering letter explaining the purpose of
the study, who the researchers were, and the process that
would be followed regarding responses together with a three-
page questionnaire. The completed, anonymous questionnaire
was to be sent back in a blank envelope enclosed in a second,
coded outer envelope. All returned envelopes were processed
by an independent third party, blinded to the study purpose,
who checked the envelopes received against the original
mailing list. The third party then sent a second mailing to all
non-responders, again without the researchers being aware of
respondents' identities.' After the second round was
completed, 344 responses were received (a 70% overall
response rate); 289 were valid responses, and the remaining 55
were the result of invalid addresses (most of whom were no
longer employed at the hospital).
The questionnaire itself contained two questions on
respondents' willingness to participate in phase I HIV vaccine
trials as healthy volunteers - the first and last questions of the
survey instrument. The remaining questions investigated
willingness to recruit their patients into vaccine trials (phase
ill), and the reasons underlying participants' statements. All
questions referred to the hypothetical use of a DNA subunit
vaccine, not a live attenuated vaccine.
Data were analysed using SAS version 8.0 (SAS Corporation,
Cary, USA). We dichotomised participant age into less than or
equal to 40 years (versus over 40 years) of age; the proportion
of time spent in clinical practice was divided into part-time
clinical practice (less than 75% of time spent seeing patients)
versus active clinical practice (more than 75% of time spent
with patients). Chi-square and Fisher's exact tests were used to
test for differences between proportions. Multiple logistical
regression was used to test associations after adjustment for
various participant characteristics; such adjustments did not
alter the study results substantially, and as a result the
unadjusted associations are reported here. Ethical approval for
the study was provided by Subcommittee C, the Research
Ethics Committee of the Faculty of Health Sciences, University
of Stellenbosch.
RESULTS
Table I describes the demographic and professional
characteristics of the 289 physicians responding to the survey.
The first question of the survey investigated subjects'
willingness to participate in HIV vaccine trials. Twenty per cent
of respondents (N = 58) stated that they would be willing to
participate, 39% (113) indicated that they would not participate,
and 41 % (118) said they were unsure. Female doctors were
significantly less likely to be willing to participate compared
with male doctors (P = 0.001). Of the physicians who expressed
willingness to participate, most (76%, N =44) gave as their
motivation concern over the magnitude of the HIV pandemic
and the urgency of finding a solution via scientific research.
The concerns associated \'"ith possible vaccine trial
participation are shown in Table ll. Of those surveyed, 81 %
(N = 234) cited the potential for vaccine-induced infection as a
major barrier to participation. Testing HIV-positive due to
serological response after vaccination was cited as a concern by
68% of respondents, and was cited more often by female
doctors, younger doctors, and doctors in active clinical practice
(P = 0.07, 0.007 and 0.035, respectively). In addition, 59% of the
sample indicated that concern about the effect of testing HIV-
positive on their medical careers was a barrier to trial
participation. This was more often a concern of younger
doctors (with 73% of young doctors versus 55% of older
Table I. Participant demographic and professional characteristics
umber
Characteristic (N =289) Percentage·
Age (yrs)
21 - 30 67 23
31-40 119 41
41 - 50 58 20
51 - 60 38 13
> 60 6 2
Gender
Female 95 33
Male 190 67
Professional title
Consultant 119 41
Registrar 113 39
Medical officer 26 9
Community service 6 2
Other (including interns) 21 7
Fraction of time spent in clinical
practice (%)
~25 38 13
26 - 50 32 11
51 -75 77 27
? 76 138 48
'Percentages may sum to slightly more or less than 100 due to rounding.
Table n. Specific concerns regarding HIV vaccine trials among the
289 responding physicians
Number noting
concern/number
responding Per-
to item· centage
Concerns regarding physicians' own
participation
Potential of vaccine to cause infection 220/271 81
Insurance/bond application denial 209/265 79
Testing HIV-positive without being 193/268 72
infected
Effectiveness of vaccine 171/256 67
Effect of testing HlV-positive on 193/256 75
medical career
Possibility of receiving placebo 72/248 29
and not vaccine
Other 47/125 38
Physicians' perceptions of patients'
concerns
Potential of vaccine to cause infection 273/277 99
Testing HlV-positive after vaccine 242/267 91
Effectiveness of vaccine 225/256. 88 miD:Insurance/bond application denied 233/254 92
Social discrimination 201/250 80
Receiving placebo and not vaccine 166/254 65
Other concerns 24/88 27
"'Participants could cite more than one concern. The denominators for each item vary
slightly because not all participants provided a response to each item.
I
doctors reporting this concern, P = 0.003) and those in active
clinical practice (with 73% of those in active practice versus
61 % of those not in active practice citing this concern,
P = 0.044).
Overall, 39% of respondents (N = 113) stated that they would
not be willing to recruit patients, 24% (69) were uncertain
about recruitment, and only 37% (l07) were willing to recruit.
Female doctors were less likely to be willing to recruit patients
(22%, versus 44% for male doctors; P = 0.002). Willingness to
participate in vaccine trials was strongly associated with
willingness to recruit patients into trials -77% of doctors
willing to participate in the trials themselves were also willing
to recruit patients, while only 27% of doctors not willing to
participate stated that they were prepared to recruit patients
(P < 0.00l).
The final question of the survey asked again about subjects'
willingness to participate in vaccine trials to evaluate whether
the act of completing the questionnaire and thinking through
trial-related concerns may change respondents' opinions. When
respondents were asked again, willingness to participate in a
vaccine trial decreased substantially to 11 % of all respondents
(N = 33) stating their willingness (compared with 20% at the
start of the survey).
DISCUSSION
This study highlights the views on HIV vaccine trial
participation among a sample of the medical profession in
South Africa. There are a number of community education
programmes underway to raise awareness of HIV vaccine trials
and the potential for participation, including projects focused
in rural KwaZulu-Natal'7 and Soweto' as well as a national
campaign.. However, there are few data available on the
willingness of various potential study populations to
participate in vaccine trials, and there are no initiatives that
target medical doctors in particular. As important 'gatekeepers'
within many communities, the attitudes of health care workers
are important determinants of local responses to HIV vaccines
and the possibility of trial participation.
Our finding of a decrease in willingness to participate in HIV
vaccine trials after being given additional information or time
to consider the decision has been documented in a number of
studies from France,'Q Thailand," and the USAY'ln addition,
the concerns regarding HIV vaccines noted by the participants
in this study parallel those expressed in similar studies from
other settings."-B The main concern regarding both doctors'
own participation, and their perceptions of patients'
willingness to participate, relate to potential of the vaccine to
cause infection. Clearly this is a central issue that requires
attention in existing community education initiatives, as well
as detailed explanation in the recruitment and informed
consent materials given to potential trial participants.
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Perhaps the most surprising aspect of these results is related
to the study population involved. Medical doctors are likely to
possess a much better understanding of the role scientific
research plays in improving health care, and we had
anticipated that the levels of willingness to participate in HIV
vaccine trials would be relatively high in this sample. The low
levels of willingness documented here emphasise the
importance of targeting HIV vaccine awareness materials at
medical doctors and other health care professionals, and
recognising more broadly that even relatively well-educa~ed
populations with substantial biomedical knowledge are likely
to have major misconceptions about experimental HIV
vaccines. As the search for an HIV vaccine continues, and
South Africa moves closer to large-scale HIV vaccine trials, this
study underscores the importance of continued, intensive
preparatory work to overcome barriers to HIV vaccine trial
participation in any population.
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